Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer

Abstract Adjuvant trastuzumab in HER2+ breast cancer reduces recurrence and mortality, and has been the standard treatment since 2006. The objective was to analyze health outcomes in the real world. Observational, retrospective study of patients with HER2+ breast cancer, stages I–III, treated with a...

Full description

Bibliographic Details
Main Authors:	J. Lluch-Gómez, V. Núñez-Álvarez, C. de la Torre-Hita, M. Bernal-Gómez, A. Campini-Bermejo, E. Perdomo-Zaldívar, L. Rodríguez-Pérez, J. Calvete-Candenas, M. J. Martínez-Bautista, E. Benítez-Rodríguez, J. M. Baena-Cañada
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-05-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-023-34429-9

Similar Items

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
by: Shannon McLaughlin, et al.
Published: (2023-01-01)

Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality
by: Salvador Gámez-Casado, et al.
Published: (2024-03-01)

Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse
by: Dukić Nikolina, et al.
Published: (2020-01-01)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
by: Sibylle Loibl, et al.
Published: (2022-09-01)

Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer
by: Caroline Muñoz, et al.
Published: (2024-03-01)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
by: Celia Nieto, et al.
Published: (2019-06-01)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
by: Chau Dang, et al.
Published: (2022-05-01)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021-05-01)

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
by: Nadine Norton, et al.
Published: (2018-06-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.
by: Ali Hajjar, et al.
Published: (2019-01-01)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019-11-01)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
by: Baubek Spanov, et al.
Published: (2022-01-01)

5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial
by: J. Gligorov, et al.
Published: (2021-04-01)

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
by: Justin M Scheer, et al.
Published: (2012-01-01)

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
by: Quentin Jacquinot, et al.
Published: (2022-09-01)

Effectiveness of adjuvant trastuzumab in daily clinical practice
by: Matos Erika, et al.
Published: (2014-12-01)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
by: Kong X, et al.
Published: (2019-07-01)

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer
by: Emma Franco-Mateos, et al.
Published: (2024-04-01)

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
by: Romualdo Barroso-Sousa, et al.
Published: (2022-02-01)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
by: María F. Mercogliano, et al.
Published: (2017-12-01)

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
by: Helena Earl, et al.
Published: (2020-08-01)

Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice
by: Nathalie I. Bouwer, et al.
Published: (2020-08-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
by: Iwata, Hiroji, et al.
Published: (2019)

Prognostic analysis of the patients with HER2-positive breast cancer adjuvant treated with trastuzumab: a report of 1 246 cases
by: LI Yuefeng, HONG Jin, LI Zhian, RUAN Guodong, CHEN Weiguo
Published: (2023-09-01)

Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
by: Anh Quynh Nguyen, et al.
Published: (2024-01-01)

Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
by: William Leung, et al.
Published: (2016-08-01)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022-09-01)

Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
by: Ibrahim Sadek, et al.
Published: (2017-09-01)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo G Jr, et al.
Published: (2016-05-01)

P004 Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial
by: F. Cao, et al.
Published: (2023-03-01)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
by: Scott A Wu, et al.
Published: (2023-09-01)

NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
by: Nathalie I. Bouwer, et al.
Published: (2019-05-01)

Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.
by: Wenjin Yin, et al.
Published: (2011-01-01)

Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids.
by: Cristina E Rodríguez, et al.
Published: (2015-01-01)

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
by: Paula Cabello, et al.
Published: (2023-04-01)